Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348412

	registered interest
	date	03/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Equipment: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether NHS England plans to establish reference prices for medical devices beyond those named in the Commissioning Intentions for 2015-16.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	1018
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>The commissioning intentions state NHS England will look at excluded devices and some drugs. The process began with implantable cardiac devices, bone anchored hearing devices and transcatheter aortic valve implantation, and proceeded to cover all excluded devices.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 10/06/2015 15:53:16 answering member 3988 label Biography information for Ben Gummer
	tabling member	1506 label Biography information for Andrew Gwynne

348016

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Sheffield
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people were waiting to see a GP for more than one week in (a) Sheffield, Heeley constituency and (b) Sheffield in each year since 2010.
	tabling member constituency	Sheffield, Heeley
	tabling member printed	Louise Haigh
	uin	703
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>Data on waiting times to see a general practitioner is not collected.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 10/06/2015 16:00:53 answering member 1201 label Biography information for Alistair Burt
	tabling member	4473 label Biography information for Louise Haigh

347966

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of the effects of the decision by the Cancer Drugs Fund not to fund olaparib for patients with BRCA-mutated ovarian cancer.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	704
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>The operation of the Cancer Drugs Fund (CDF), including the evaluation of new drugs for potential inclusion in the Fund, is a matter for NHS England’s CDF panel to consider alongside applications for new drugs to be added to the Fund on the basis of the clinical benefit a drug provides in relation to its cost. NHS England’s decision summary for olaparib as a maintenance treatment for relapsed BRCA-mutated high grade ovarian cancer can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2015/05/cdf-decision-olaparib.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2015/05/cdf-decision-olaparib.pdf</a></p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence is currently consulting on draft guidance on olaparib for use in certain ovarian, fallopian tube, and peritoneal cancers. This consultation is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/GID-TAG481/consultation" target="_blank">www.nice.org.uk/guidance/indevelopment/GID-TAG481/consultation</a></p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2015 16:35:56 answering member 4020 label Biography information for George Freeman
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

347967

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ovarian Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to offer personalised medicines to women with BRCA-mutated ovarian cancer with limited treatment options.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	705
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>NHS England provides BRCA testing services for women at high risk of breast and ovarian cancer.</p><p> </p><p> </p><p> </p><p>Following the National Institute for Health and Care Excellence’s (NICE) updated clinical guideline on familial breast cancer published in June 2013, NHS England is currently considering whether to widen its offer of testing. NICE is also consulting on its draft technology appraisal guidance on the use of the new PARP inhibiter, olaparib (Lynparza) which is targeted at BRCA positive ovarian cancer. In addition, through initiatives like the 100,000 Genomes Project we will in time provide more insights into personalised treatments for ovarian cancer.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2015 16:26:19 answering member 4020 label Biography information for George Freeman
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

347968

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients benefit from scientific research into personalised medicines.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	706
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>Personalised or ‘precision’ medicine is expected to transform healthcare in the coming decades through more accurate diagnosis leading to better predictions of prognosis and better targeted treatments, fewer side effects and improved medicines efficacy. Improved understanding of the role played by genetics in the development of disease has been directly supported through the 100,000 Genomes Project the main phase of which was launched by the National Health Service in April 2015 and aims to sequence 100,000 whole human genomes for certain rare/inherited diseases and cancers by the end of 2017. In addition, the National Health Service will be working closely with the Precision Medicine Catapult to accelerate the development and adoption of precision medicine throughout the NHS.</p><p> </p><p> </p><p> </p><p>Combined with the Early Access to Medicines Scheme and the Accelerated Access Review of IMMT, the Government is actively working to support faster patient access to better targeted and personalised medicines.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2015 16:39:44 answering member 4020 label Biography information for George Freeman
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

348089

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of recent research by the Institute of Cancer Research into the effect of a genetically created herpes-based virus as a remedy against forms of skin cancer.
	tabling member constituency	Neath
	tabling member printed	Christina Rees
	uin	721
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>Talimogene laherparepvec (T-Vec) is still undergoing clinical trials and has not yet been licensed for the treatment of malignant melanoma by the regulatory authorities in either the United States or the European Union.</p><p> </p><p> </p><p> </p><p>The Department has made no specfic assessment of research findings into its use to treat melanoma.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 868 question first answered 10/06/2015 16:40:53 answering member 4020 label Biography information for George Freeman
	tabling member	4525 label Biography information for Christina Rees

347996

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions he has had with his EU counterparts on reviewing EU legislation on access to cancer drugs for children.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	824
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>The European Union Regulation on Paediatric Medicines has been successful in increasing the number of medicines authorised to treat diseases that affect children and it has led to an overall increase in the number of paediatric clinical trials in the United Kingdom and across Europe in many therapeutic areas, including oncology.</p><p> </p><p> </p><p> </p><p>However, it is recognised that the system of class waivers for adult conditions, which was intended to prevent unnecessary studies in children, may have acted as a disincentive for the development of medicines to treat rare paediatric cancers. Medicines regulators are aware of this issue and have been taking steps to encourage development of more medicines for paediatric-specific conditions in the oncology field and other therapeutic areas, within the existing legislation.</p><p> </p><p> </p><p> </p><p>They are reviewing anti-cancer paediatric investigation plans (PIPs), which are required by the legislation for new medicines, on the basis of mechanism of action and are reviewing the class waivers in this area. UK representatives are strongly supporting this on-going work at a European level to widen access to clinical trials for medicines for rare diseases, including cancer, in children and will continue to press for changes to the system of class waivers in collaboration with European Medicines Agency, which issues decisions on PIPs and other European regulators. The review of the class waiver system is close to completion and publication is expected in the next few months.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2015 16:39:16 answering member 4020 label Biography information for George Freeman
	tabling member	4131 label Biography information for Jim Shannon

347950

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, in which of the seven demonstrator sites the NHS National Diabetes Prevention Programme began operating.
	tabling member constituency	Leicester East
	tabling member printed	Keith Vaz
	uin	828
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>The diabetes prevention programme announced seven demonstrator sites on 12 March 2015:</p><p> </p><p> </p><p> </p><p>- Birmingham South and Central Clinical Commissioning Group (CCG)</p><p> </p><p>- Bradford City CCG</p><p> </p><p>- Durham County Council</p><p> </p><p>- Herefordshire CCG/Local Authority (LA)</p><p> </p><p>- Medway CCG/LA</p><p> </p><p>- Salford CCG/LA</p><p> </p><p>- Southwark Council and CCG</p><p> </p><p> </p><p> </p><p>The demonstrator sites were specifically chosen with different levels of service provision to provide important learning in establishing the National Diabetes Prevention Programme. Six demonstrator sites have existing type 2 diabetes prevention services.</p><p> </p><p> </p><p> </p><p>The programme is currently working with the demonstrator sites to jointly develop plans to amend and scale up their services. This will inform the development of the programme.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2015 14:22:16 answering member 3918 label Biography information for Jane Ellison
	tabling member	338 label Biography information for Keith Vaz

347951

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many patients have been identified as possibly diabetic by the NHS Health Check in the last 12 months.
	tabling member constituency	Leicester East
	tabling member printed	Keith Vaz
	uin	829
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>This information is not held centrally.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) is currently working with the health &amp; social care information centre to establish a national data standard which will allow uniformed reporting on the NHS Health Check. PHE is also exploring options for the introduction of a national for representational data collection system for the NHS health check programme.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2015 14:59:25 answering member 3918 label Biography information for Jane Ellison
	tabling member	338 label Biography information for Keith Vaz

347997

	registered interest
	date	02/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans the NHS has to use the drug T-Vec for the treatment of skin cancer.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	868
	answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>Talimogene laherparepvec (T-Vec) is still undergoing clinical trials and has not yet been licensed for the treatment of malignant melanoma by the regulatory authorities in either the United States or the European Union.</p><p> </p><p> </p><p> </p><p>The Department has made no specfic assessment of research findings into its use to treat melanoma.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 721 question first answered 10/06/2015 16:40:53 answering member 4020 label Biography information for George Freeman
	tabling member	4131 label Biography information for Jim Shannon